使用创新的模拟方法提高谷氨的口服生物可用性
Naibo Yin1, Paul W R Harris2,3, Mengyang Liu1,3
1School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.
Pharmaceutics
|March 27, 2025
概括
化学改性谷氨 (GSH) 类似物是为了改善口服生物可用性而开发的. 一种N-甲基化衍生物,化合物1.70,显著提高了血半衰期和生物可用性,表明了治疗潜力.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 谷氨 (GSH) 是一种至关重要的内源抗氧化剂.
- 由于降解和吸收问题,口服生物利用率低 (<1%) 限制了GSH的治疗用途.
- 提高GSH口服生物利用率是提高其疗效的关键.
研究的目的:
- 设计和合成具有改善口服生物可用性的新型谷氨 (GSH) 类似物.
- 评估合成的GSH衍生物的生物可用性,抗氧化活性和毒性.
- 为潜在的治疗应用确定一个有前途的GSH类似物.
主要方法:
- 通过Fmoc固相合成合成七种GSH衍生物,包括刻板化学改变和N-甲基化类似物.
- 使用RP-HPLC,ESI-MS,FTIR和NMR光谱进行表征.
- 对Caco-2细胞的细胞毒性评估,对UVA辐射纤维细胞的抗氧化能力,酶降解耐受性和与GSH代谢酶的相互作用.
主要成果:
- 化合物1.70,一种N-甲基化氨酸衍生物,表现出优越的酶降解耐受性.
- 与原生GSH相比,化合物1.70证明了增强的细胞活力和抗氧化活性.
- 在体内研究显示,血半衰期增加了16.8倍,口服生物可用性增加了16.1倍.
结论:
- 化学修饰,特别是GSH的N-甲基化,有效地提高了口服生物可用性.
- 化合物1.70由于其改善的药理动力学和药理动力学特性,具有治疗应用的巨大潜力.
- 需要对化合物1.70进行进一步的临床研究和开发.
相关概念视频
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
122
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
122
Drug Metabolism: Phase II Reactions
3.5K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.5K
Factors Influencing Bioavailability: First-Pass Elimination
5.9K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
5.9K
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Phase II Reactions: Glucuronidation
198
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
198
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
162
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
162


